Cencora, Inc. (NYSE:COR) Shares Sold by TD Private Client Wealth LLC

TD Private Client Wealth LLC lessened its stake in Cencora, Inc. (NYSE:COR) by 2.6% in the 4th quarter, Holdings Channel reports. The firm owned 6,810 shares of the company’s stock after selling 179 shares during the period. TD Private Client Wealth LLC’s holdings in Cencora were worth $1,530,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in COR. Whittier Trust Co. lifted its position in Cencora by 0.6% in the fourth quarter. Whittier Trust Co. now owns 7,856 shares of the company’s stock valued at $1,765,000 after acquiring an additional 44 shares during the last quarter. Symmetry Partners LLC grew its position in Cencora by 8.2% during the fourth quarter. Symmetry Partners LLC now owns 968 shares of the company’s stock worth $218,000 after buying an additional 73 shares during the period. Blueshift Asset Management LLC purchased a new stake in shares of Cencora in the fourth quarter valued at about $247,000. Teacher Retirement System of Texas lifted its holdings in shares of Cencora by 7.6% in the fourth quarter. Teacher Retirement System of Texas now owns 121,640 shares of the company’s stock valued at $27,330,000 after purchasing an additional 8,600 shares in the last quarter. Finally, Royal London Asset Management Ltd. lifted its stake in shares of Cencora by 2.8% during the fourth quarter. Royal London Asset Management Ltd. now owns 101,284 shares of the company’s stock valued at $22,756,000 after buying an additional 2,711 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Trading Down 0.3 %

Shares of COR stock opened at $266.91 on Friday. The firm has a fifty day moving average of $250.62 and a 200-day moving average of $240.03. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $271.08. The stock has a market cap of $51.76 billion, a price-to-earnings ratio of 37.97, a P/E/G ratio of 1.31 and a beta of 0.51.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a dividend of $0.55 per share. The ex-dividend date was Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.82%. Cencora’s dividend payout ratio (DPR) is currently 31.29%.

Analyst Ratings Changes

Several equities analysts recently issued reports on COR shares. Evercore ISI upped their price objective on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Wells Fargo & Company increased their price objective on shares of Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a research report on Friday, March 14th. JPMorgan Chase & Co. raised their price target on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a report on Friday, January 24th. StockNews.com raised shares of Cencora from a “hold” rating to a “buy” rating in a report on Wednesday, March 12th. Finally, Mizuho initiated coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $280.20.

Insider Transactions at Cencora

In related news, EVP Silvana Battaglia sold 5,000 shares of the firm’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the transaction, the executive vice president now directly owns 15,374 shares of the company’s stock, valued at approximately $3,724,197.76. This trade represents a 24.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Lazarus Krikorian sold 2,000 shares of Cencora stock in a transaction on Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the transaction, the chief accounting officer now directly owns 20,154 shares of the company’s stock, valued at approximately $5,241,249.24. This trade represents a 9.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,970 shares of company stock valued at $2,998,670 in the last ninety days. 10.80% of the stock is currently owned by corporate insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.